Advertisement

Characterization of the New Cytomygalovirus Immunoglobulin Preparation for Intravenous Use

  • R. Schweitzer
Chapter
Part of the Developments in Hematology and Immunology book series (DIHI, volume 10)

Abstract

On the basis of the occurrence of antibodies against cytomegalovirus, the incidence of this infection in Europe and North America is about 60–70% of the total population. CMV infections are, in most cases, clinically inapparent. Alterations in the immunological defence system, caused for example by pregnancy, the presence of malignant disease, immunosuppressive or cytostatic therapy, as well as by massive transfusions of blood, are the commonest causes of an increased incidence of CMV infection, combined with a high rate of clinically overt illness (Fig. 1). This applies both to primary CMV infections as well as to the reactivation of latent virus in the body.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Condie RM, Hall BL, Howard RJ, Fry D, Simmons RL, Najarian JS. Treatment of life-threatening infections in renal transplant recipients with high-dose intravenous human IgG. Transplant Proc II 1979; 1: 66–8.Google Scholar
  2. 2.
    Nicholls AJ, Brown CB, Edwar N, Cuthbertson B, Yap PL, McClelland DBL. Hyperimmune immunoglobulin for cytomegalovirus infections. Lancet 1983;i:532–3.CrossRefGoogle Scholar
  3. 3.
    O’Reilly RJ, Riech L, Gold J, et al. A randomized trial of intravenous hyperimmune globulin for the prevention of cytomegalovirus (CMV) infections following marrow transplantation: Preliminary results. IX. Intern Congress of the Transplant Society, Brighton 1982 (abstract).Google Scholar
  4. 4.
    Winston DJ, Pollard RB, Ho WG, et al. Cytomegalovirus immune plasma in bone marrow transplant recipients. Ann Intern Med 1982; 97: 11–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Stephan W. Undegraded human immunoglobulin for intravenous use. Vox Sang 1975; 28: 422–37.PubMedCrossRefGoogle Scholar
  6. 6.
    Stephan W, Dichtelmiiller H. Beta-propiolacton als sterilisierendes Agens bei der Herstellung eines inträvenosen Immunoglobulin-Präparates. Arzneim Forsch/Drug Res 1983; 33: 1230–1.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1984

Authors and Affiliations

  • R. Schweitzer

There are no affiliations available

Personalised recommendations